Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
McKinnon, C., Nandhabalan, M., Murray, S. A. & Plaha, P. Glioblastoma: Scientific presentation, analysis, and administration. BMJ 374, n1560 (2021).Article
...
Responses to Iclusig doubled that of Gleevec in sufferers with Philadelphia chromosome-positive acute lymphoblastic leukemia, analysis confirmed.Sufferers with newly recognized Philadelphia chromosome-positive acute...
